Glaucoma Supplements: What the Human Trials Actually Show
Glaucoma damages the optic nerve, and the only treatment proven to slow that damage is lowering eye pressure. No supplement has been shown to stop glaucoma, restore lost vision, or replace the drops, laser, or surgery your eye doctor prescribes.
The question is still fair. Some people keep losing visual field even when pressure is controlled, so researchers have tested nutrients that might protect nerve cells directly. A few trials show signals. Others show nothing.
This guide gives the dose, patient count, duration, and exact measurement that changed. It also names the trials that failed. Reviews call this evidence promising but not definitive [25]. Use it to prepare for your ophthalmologist visit, not to self-treat.
What glaucoma does to the optic nerve
The optic nerve carries signals from the retina to the brain. In glaucoma, retinal ganglion cells and their fibers are damaged, usually slowly, and peripheral vision is often lost first.
Raised intraocular pressure (IOP) is the main risk factor you can change. Every treatment proven to slow glaucoma lowers IOP: eyedrops, laser, and surgery. That is the standard this article measures against.
Glaucoma can still progress when pressure looks controlled. That gap is why neuroprotection is studied. Neuroprotection means supporting nerve cells through a mechanism separate from pressure. In glaucoma, it remains experimental.
The trials below include open-angle and normal-tension glaucoma, where damage occurs at normal pressure.
How to read a glaucoma supplement claim
Supplement marketing lumps all eye benefits together. The research does not. Identify which outcome moved. This article covers glaucoma only; the cataract supplements guide and the dry eye supplements guide cover those separate conditions.
- Intraocular pressure. A 1.6 mmHg change in a 40-patient trial is a trial result, not proof that blindness is delayed.
- Retinal function. The pattern electroretinogram (PERG) and photopic negative response (PhNR) measure electrical activity in retinal ganglion cells. They are sensitive research tools, not what you see on a chart.
- Visual field. Mean deviation, pattern standard deviation, and the visual field index describe field loss. A change is closer to daily vision, but still trial-bound.
- Macular pigment optical density. A measure of pigment in the macula. It can rise without any change in structure or acuity.
- Risk association. Observational studies compare habits. They cannot prove cause.
- Animal data. Useful for hypotheses, not evidence that a supplement helps a person.
A nutrient can move one outcome and do nothing for the others. Ask which one changed.
Clinically proven means little without the outcome, dose, and duration.
The nutrients with human evidence
Eight nutrients have enough human evidence to discuss. Six have human intervention studies; CoQ10 has a review only, and the B vitamin evidence is largely observational. Trial details matter more than the marketing summary. A systematic review of nutraceuticals in glaucoma found many candidates and few definitive outcomes [26].
Nicotinamide (vitamin B3)
Nicotinamide is a form of vitamin B3 with the busiest recent trial record here.
Hui and colleagues ran a double-masked randomized crossover in 57 treated glaucoma patients [1]. The dose was 1.5 g/day for six weeks, then 3.0 g/day for six weeks. PhNR Vmax improved 14.8% (95% CI 2.8-26.9, P=.02) versus 5.2% on placebo (P=.27), and the Vmax ratio improved 12.6% (P=.002). A trend for improved visual field mean deviation was observed, with 27% of patients improving by at least 1 dB and fewer deteriorating (4% versus placebo; P=.02). The study was short-term.
De Moraes and colleagues randomized 42 patients in a phase 2 double-blind placebo-controlled trial; 32 completed [2]. They took ascending nicotinamide 1,000-3,000 mg plus pyruvate 1,500-3,000 mg. The median improving visual field test locations was 15 versus 7 (P=.005). Pattern standard deviation improved; mean deviation and the visual field index did not. There were no serious adverse events, and median follow-up was 2.2 months.
Ha and colleagues studied 53 normal-tension glaucoma patients in a double-masked placebo-controlled crossover [3]. At 1 g/day for six weeks, then 2 g/day for six weeks, PhNR peak-to-trough and b-wave amplitudes improved versus placebo (P=.045 and P=.032). Visual field differences at 12 weeks were not significant.
A 2026 review of 13 reports from 8 human studies found preliminary short-term signals and inconsistent visual field effects, with evidence insufficient for routine high-dose use [4].
Bottom line: short-term retinal signals, no long-term proof.
Citicoline
Citicoline has both positive and negative trials.
An international multicenter double-masked placebo-controlled crossover gave patients with controlled open-angle glaucoma 500 mg/day of oral citicoline for three months per arm [5]. The Visual Function Questionnaire-25 composite improved versus placebo (P=.0413), most in patients with worse baseline vision-related quality of life.
A Jarrow Formulas citicoline product at Agape provides 250 mg per capsule, so check the label serving against the trial's 500 mg per day with your doctor.
A randomized trial of 73 patients compared vitamin C, DHA, citicoline, and DHA plus citicoline for three months [6]. The combination improved mean defect from -9.52 to -7.85 dB and improved the visual field index (P=.001). Citicoline alone did not show the same combined effect.
A 2023 systematic review by Prinz and colleagues covered 10 studies and 424 patients [7]. It found no significant differences in IOP, mean deviation, retinal nerve fiber layer, or PERG P50-N95 amplitude between citicoline and control, and no improvement from baseline. The authors concluded there is insufficient evidence that citicoline slows progression. One trial of citicoline eyedrops reported slower progression on some measures, not oral supplements [8].
Bottom line: quality-of-life signals, but a 424-patient review found no structural or field benefit.
Ginkgo biloba
Ginkgo biloba shows why one small trial is not enough.
Quaranta and colleagues ran a double-masked randomized crossover in 27 normal-tension glaucoma patients [9]. The dose was 40 mg three times daily (120 mg/day) for four weeks, with an eight-week washout. Mean deviation improved from 11.40 to 8.78 dB, corrected pattern standard deviation improved, and IOP did not change.
Guo and colleagues used the same dose for four weeks in 35 randomized normal-tension glaucoma patients (28 completed) [10]. They found no difference in visual field mean deviation or contrast sensitivity (P>.2 for all). This is the key null trial.
An observational chart review of 332 subjects followed patients for about 24 months [11]. Mean deviation improved with anthocyanins (-6.44 to -5.34) and ginkgo (-5.25 to -4.31), but the design cannot prove cause.
A review of 33 intervention trials, including 21 randomized trials, found flavonoids may benefit ocular blood flow and possibly visual field loss, but the evidence was not conclusive [12].
The ginkgo biloba guide covers extract types and dosing in more detail.
Bottom line: one small positive trial, one equally small null trial, no proof of progression benefit.
Bilberry, anthocyanins, and French maritime pine bark
Bilberry and pine bark are often sold together; one small study tested the pair.
Manabe and colleagues enrolled 18 subjects (29 eyes) with primary open-angle glaucoma on one to three medications [13]. They took pine bark 40 mg plus bilberry 90 mg daily for four weeks. Mean IOP fell from 17.2 to 15.7 mmHg, an 8.7% reduction (P=.0046). Half the subjects responded, 33% were unchanged, and 17% rose. There was no placebo group.
A Pure Encapsulations bilberry extract at Agape provides 160 mg per capsule and is standardized to 25% anthocyanosides, so compare the label with the 90 mg of bilberry extract used in the study.
The Shim chart review also reported visual field improvement with anthocyanins, but it was retrospective [11]. A 2025 review lists both among nutraceuticals with emerging evidence, not established benefit [25].
Bottom line: a small open-label pressure signal, with no placebo control.
Lutein, zeaxanthin, and meso-zeaxanthin
These carotenoids form macular pigment. The glaucoma trial measured pigment, not pressure.
Loughman and colleagues ran a double-masked randomized placebo-controlled trial in 62 people with open-angle glaucoma: 42 active and 20 placebo [14]. The active group took 10 mg lutein, 2 mg zeaxanthin, and 10 mg meso-zeaxanthin for 18 months. Macular pigment optical density increased at every visit, and mesopic contrast sensitivity under glare improved at 18 months. No other structural or functional changes appeared.
Do not import the macular degeneration story. AREDS2 was tested for AMD, not glaucoma, and this trial showed no other structural or functional benefit. The macular degeneration supplements guide covers that separate body of evidence.
Bottom line: pigment and glare contrast improved; structure and standard function did not.
Palmitoylethanolamide (PEA)
PEA has one small crossover trial and a small meta-analysis.
Rossi and colleagues randomized 40 stable glaucoma patients on topical monotherapy in a single-blind crossover [15]. PEA was given at 600 mg once daily. PERG P50 amplitude improved by 0.56 microvolts (P<.001), IOP fell 1.6 mmHg (P<.001), and quality of life improved 6.7 points (P<.001).
A 2025 systematic review found 6 studies and 199 patients, with only 3 in the meta-analysis [16]. PEA significantly reduced IOP on a small evidence base.
Bottom line: consistent small signals, but only 199 patients in total.
Coenzyme Q10
Coenzyme Q10 is often described as a mitochondrial antioxidant. In glaucoma, human evidence is thin.
A 2019 review by Martucci and Nucci summarized mechanistic and early clinical evidence for CoQ10 as a neuroprotective adjunct, and identified no large randomized outcome trial [17].
Bottom line: promising mechanism, no outcome trial. Not enough to recommend.
B vitamins and homocysteine
Homocysteine is an amino acid. Lowering it might help the optic nerve, but human data do not settle that.
A 2025 study by Tribble and colleagues found dysregulated one-carbon metabolism in animal models of glaucoma [18]. Supplementing B6, B9, B12, and choline was neuroprotective in acute and chronic models. Human genetic and serum data did not show homocysteine as causative. This is preclinical.
A meta-analysis of 8 studies and 262,189 patients found high-dose vitamin A associated with lower glaucoma prevalence (OR 0.63, 95% CI 0.53-0.76) and B vitamins with lower prevalence (OR 0.71, 95% CI 0.64-0.80) [19]. Vitamins C, D, and E were not significant. This is observational and cannot show cause.
Li and colleagues examined homocysteine, folate, B12, B6, and MTHFR in normal-tension glaucoma and found no association, again observational [20].
Bottom line: a plausible mechanism and risk associations, no trial proof of protection.
What the diet and lifestyle studies show
Diet studies compare habits and outcomes; they cannot prove that changing one food changes glaucoma.
Nitrate and green leafy vegetables. Kang and colleagues followed 1,483 incident primary open-angle glaucoma cases in two large cohorts [21]. The highest versus lowest dietary nitrate quintile (about 240 versus 80 mg/day) had a rate ratio of 0.79 (95% CI 0.66-0.93). Green leafy vegetables at 1.45 or more servings per day versus 0.31 gave a rate ratio of 0.82 (95% CI 0.69-0.97).
The Rotterdam Study found a similar direction in 173 incident cases [22]. Each 10 mg/day higher nitrate was associated with an odds ratio of 0.95 (95% CI 0.91-0.98), with no association with IOP.
The signal is consistent across two studies, but it is a risk association, not a prescription.
Caffeine. In an observational analysis of 121,374 UK Biobank participants, habitual caffeine was weakly associated with lower IOP [23]. Mendelian randomization did not support a causal effect on IOP, and the overall glaucoma association was null. Compared with the lowest genetic-risk quartile consuming no caffeine, the highest genetic-risk quartile consuming at least 321 mg/day had 3.90-fold higher glaucoma prevalence (interaction P=.0003).
Exercise. A review of 16 studies found moderate aerobic exercise causes transient IOP reduction, while high-intensity resistance exercise and weightlifting cause transient IOP elevation [24]. Higher fitness may be protective, and more daily activity may be associated with less visual field progression.
Comparison table
| Nutrient | Best human evidence | Dose studied | What changed in the trial | Evidence strength | Key caution |
|---|---|---|---|---|---|
| Nicotinamide (B3) | 3 small trials; 2026 review [1-4] | 1.5-3 g/day; 1-3 g/day with pyruvate | PhNR Vmax +14.8% vs +5.2%; median improving field locations 15 vs 7 | Short-term, mixed | Liver enzymes, nausea, flushing |
| Citicoline | Crossover [5]; 424-patient review [7] | 500 mg/day oral, 3 months | VFQ-25 improved (P=.0413); review found no IOP, field, or RNFL difference | Conflicting | Oral evidence inconsistent; drops are another route |
| Ginkgo biloba | 27-patient positive trial [9]; 35 randomized, 28 completed, null trial [10] | 120 mg/day, 4 weeks | MD 11.40 to 8.78 dB in one; no difference in the other | Weak, inconsistent | Bleeding risk; stop before surgery |
| Bilberry plus pine bark | 18-subject open-label study [13] | Pine bark 40 mg plus bilberry 90 mg daily, 4 weeks | Mean IOP 17.2 to 15.7 mmHg (8.7%) | Weak, no placebo | Blood glucose and bleeding caution |
| Lutein, zeaxanthin, meso-zeaxanthin | 62-patient randomized trial [14] | 10 mg + 2 mg + 10 mg, 18 months | Macular pigment rose; glare contrast improved | Moderate for pigment, weak for vision | No structural or standard function benefit |
| PEA | 40-patient crossover [15]; 199-patient review [16] | 600 mg once daily | PERG P50 +0.56 microvolts; IOP -1.6 mmHg | Small | Small evidence base |
| CoQ10 | Mechanistic review only [17] | No established dose | No large randomized trial | Very limited | May reduce warfarin effectiveness |
| B vitamins | Observational meta-analysis [19] | High-dose intake, not a trial dose | Lower prevalence with vitamin A and B vitamins | Observational only | B6 neuropathy; vitamin A toxicity |
Safety and interactions
Supplements are not risk-free, and the risks land hardest in people already taking medication.
- Nothing here replaces pressure treatment. Do not stop or reduce drops, laser treatment, or surgery for a supplement.
- Ginkgo: bleeding risk with warfarin, aspirin, clopidogrel, and other anticoagulants or antiplatelets. Stop before surgery. May lower the seizure threshold. Not for pregnancy without clinician advice.
- Nicotinamide at gram doses: nausea, flushing, and liver enzyme elevation. The trials used 1-3 g/day under supervision. Check liver enzymes with long-term use. Not routine.
- High-dose vitamin B6: peripheral neuropathy with sustained high intake. Do not stack B-complex products.
- Vitamin A: high-dose preformed vitamin A is hepatotoxic and teratogenic. Avoid in pregnancy. Beta-carotene is not retinol.
- CoQ10: may reduce warfarin effectiveness.
- Bilberry and anthocyanins: may affect blood glucose and bleeding risk.
- Magnesium: caution in kidney disease.
- Caffeine: can raise IOP transiently. Discuss intake if you have a family history, pseudoexfoliation, or high genetic risk.
- Cannabis: lowers IOP briefly, about 3-4 hours, but is not recommended because of side effects, impairment, and impractical dosing.
- Special groups: pregnancy, breastfeeding, children, kidney disease, liver disease, and polypharmacy warrant a conversation with your ophthalmologist and pharmacist.
How to choose a product if you and your eye doctor decide to try one
Treat a supplement as a structured experiment, not a permanent purchase.
- Match the dose to a trial. A product with 50 mg of ginkgo is not the 120 mg/day that was tested.
- Choose a standardized extract. Look for a standardized percentage or a named marker compound.
- Prefer third-party testing. A certificate of analysis matters more than a front-of-bottle claim. Agape Nutrition's third-party testing page explains what that certificate covers.
- Change one thing at a time. Otherwise you cannot tell what helped or what caused a side effect.
- Set a review window. Trials ran from four weeks to 18 months. An 8-12 week personal trial with a symptom and visual field log is reasonable.
- Do not stop or change your drops. Keep every pressure appointment and field test.
- Tell your pharmacist. Bring the bottle, not just the product name.
Agape Nutrition carries practitioner-grade options in several of these categories, and its nutritional consultation service can help you compare labels. Confirm with your eye doctor and pharmacist before starting.
What to ask your eye doctor
Bring these questions to your next appointment.
- Is my glaucoma open-angle or normal-tension, and how fast has it progressed?
- Is my pressure at target, and is there room to lower it further?
- Given my field tests and scans, is there any reason to consider a supplement?
- Which nutrient, if any, matches my situation, and at what dose and duration?
- Will it interact with my drops or other medicines, including blood thinners?
- What should we measure, and when, to decide whether to continue?
References
- Hui F, Tang J, Williams PA, et al. Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: a crossover randomized clinical trial. Clin Exp Ophthalmol. 2020. https://pubmed.ncbi.nlm.nih.gov/32721104/
- De Moraes CG, John SWM, Williams PA, et al. Nicotinamide and pyruvate for neuroenhancement in open-angle glaucoma: a phase 2 randomized clinical trial. JAMA Ophthalmol. 2022. https://pubmed.ncbi.nlm.nih.gov/34792559/
- Ha A, Kim YK, Lee CK, et al. Effects of nicotinamide supplementation in normal-tension glaucoma: a crossover placebo-controlled randomised clinical trial. Br J Ophthalmol. 2026. https://pubmed.ncbi.nlm.nih.gov/41167798/
- Giudiceandrea A, Cocuzza M, Gravina G, et al. Nicotinamide supplementation in glaucoma: a systematic review of human studies. Nutrients. 2026. https://pubmed.ncbi.nlm.nih.gov/42739057/
- Rossetti L, Goni F, Montesano G, et al. The effect of citicoline oral solution on quality of life in patients with glaucoma: the results of an international, multicenter, randomized, placebo-controlled cross-over trial. Graefes Arch Clin Exp Ophthalmol. 2023. https://pubmed.ncbi.nlm.nih.gov/36639525/
- Anton A, Garcia V, Muñoz M, et al. The effect of oral citicoline and docosahexaenoic acid on the visual field of patients with glaucoma: a randomized trial. Life (Basel). 2022. https://pubmed.ncbi.nlm.nih.gov/36294916/
- Prinz J, Prokosch V, Liu H, et al. Efficacy of citicoline as a supplement in glaucoma patients: a systematic review. PLoS One. 2023. https://pubmed.ncbi.nlm.nih.gov/37768938/
- Rossetti L, Iester M, Tranchina L, et al. Can treatment with citicoline eyedrops reduce progression in glaucoma? The results of a randomized placebo-controlled clinical trial. J Glaucoma. 2020. https://pubmed.ncbi.nlm.nih.gov/32541370/
- Quaranta L, Bettelli S, Uva MG, et al. Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma. Ophthalmology. 2003. https://pubmed.ncbi.nlm.nih.gov/12578781/
- Guo X, Kong X, Huang R, et al. Effect of Ginkgo biloba on visual field and contrast sensitivity in Chinese patients with normal tension glaucoma: a randomized, crossover clinical trial. Invest Ophthalmol Vis Sci. 2014. https://pubmed.ncbi.nlm.nih.gov/24282229/
- Shim SH, Kim JM, Choi CY, et al. Ginkgo biloba extract and bilberry anthocyanins improve visual function in patients with normal tension glaucoma. J Med Food. 2012. https://pubmed.ncbi.nlm.nih.gov/22870951/
- Loskutova E, O'Brien C, Loskutov I, et al. Nutritional supplementation in the treatment of glaucoma: a systematic review. Surv Ophthalmol. 2019. https://pubmed.ncbi.nlm.nih.gov/30296451/
- Manabe K, Kaidzu S, Tsutsui A, et al. Effects of French maritime pine bark/bilberry fruit extracts on intraocular pressure for primary open-angle glaucoma. J Clin Biochem Nutr. 2021. https://pubmed.ncbi.nlm.nih.gov/33536714/
- Loughman J, Loskutova E, Butler JS, et al. Macular pigment response to lutein, zeaxanthin, and meso-zeaxanthin supplementation in open-angle glaucoma: a randomized controlled trial. Ophthalmol Sci. 2021. https://pubmed.ncbi.nlm.nih.gov/36247822/
- Rossi GCM, Scudeller L, Lumini C, et al. Effect of palmitoylethanolamide on inner retinal function in glaucoma: a randomized, single blind, crossover, clinical trial by pattern-electroretinogram. Sci Rep. 2020. https://pubmed.ncbi.nlm.nih.gov/32591562/
- Crupi L, Capra AP, Paterniti I, et al. Evaluation of the nutraceutical palmitoylethanolamide in reducing intraocular pressure (IOP) in patients with glaucoma or ocular hypertension: a systematic review and meta-analysis. Nat Prod Res. 2025. https://pubmed.ncbi.nlm.nih.gov/38269580/
- Martucci A, Nucci C. Evidence on neuroprotective properties of coenzyme Q10 in the treatment of glaucoma. Neural Regen Res. 2019. https://pubmed.ncbi.nlm.nih.gov/30530997/
- Tribble JR, Wong VHY, Stuart KV, et al. Dysfunctional one-carbon metabolism identifies vitamins B6, B9, B12, and choline as neuroprotective in glaucoma. Cell Rep Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40345183/
- Han FF, Fu XX. Vitamin intake and glaucoma risk: a systematic review and meta-analysis. J Fr Ophtalmol. 2022. https://pubmed.ncbi.nlm.nih.gov/35120728/
- Li J, Xu F, Zeng R, et al. Plasma homocysteine, serum folic acid, serum vitamin B12, serum vitamin B6, MTHFR, and risk of normal-tension glaucoma. J Glaucoma. 2016. https://pubmed.ncbi.nlm.nih.gov/26171850/
- Kang JH, Willett WC, Rosner BA, et al. Association of dietary nitrate intake with primary open-angle glaucoma: a prospective analysis from the Nurses' Health Study and Health Professionals Follow-up Study. JAMA Ophthalmol. 2016. https://pubmed.ncbi.nlm.nih.gov/26767881/
- Vergroesen JE, de Crom TOE, Blekkenhorst LC, et al. Dietary nitrate intake is associated with decreased incidence of open-angle glaucoma: the Rotterdam Study. Nutrients. 2022. https://pubmed.ncbi.nlm.nih.gov/35745220/
- Kim J, Aschard H, Kang JH, et al. Intraocular pressure, glaucoma, and dietary caffeine consumption: a gene-diet interaction study from the UK Biobank. Ophthalmology. 2021. https://pubmed.ncbi.nlm.nih.gov/33333105/
- Gildea D, Doyle A, O'Connor J. The effect of exercise on intraocular pressure and glaucoma. J Glaucoma. 2024. https://pubmed.ncbi.nlm.nih.gov/38722193/
- Liu Z, Ang GS. Nutraceuticals and neuroprotection for glaucoma-introducing the NP-10 System. Ther Adv Ophthalmol. 2025. https://pubmed.ncbi.nlm.nih.gov/41280204/
- Scuteri D, Rombola L, Watanabe C, et al. Impact of nutraceuticals on glaucoma: a systematic review. Prog Brain Res. 2020. https://pubmed.ncbi.nlm.nih.gov/32988469/
What We Recommend
These are options matched to the nutrients discussed above; confirm any product with your eye doctor and pharmacist before starting.
Nordic Naturals, ProDHA Eye 60 and 120 Softgels
Each 2-softgel serving provides 20 mg lutein, 4 mg zeaxanthin, and 845 mg DHA, which is more of both carotenoids than the Loughman trial's 10 mg lutein and 2 mg zeaxanthin but without the 10 mg meso-zeaxanthin that trial used. The 60 softgel bottle is the $53.25 size and the 120 softgel bottle is $96.30, and the label advises consulting a physician if you are allergic to iodine, use blood thinners, or anticipate surgery.
$53.25
Jarrow Formulas, Citicoline CDP Choline 60 Capsules
Each capsule provides 250 mg of citicoline, so the label serving size is what you compare with the 500 mg per day used in the oral trial.
$41.99
Pure Encapsulations, Bilberry 160 mg 120 Capsules
Each capsule provides 160 mg of bilberry extract standardized to 25% anthocyanosides.
$114.60
XYMOGEN, I-Sight 60 Capsules
A multi-ingredient ocular antioxidant formula that combines lutein, zeaxanthin, and bilberry with taurine, zinc, N-acetyl cysteine, alpha-lipoic acid, quercetin, and lycopene, covering the carotenoid and bilberry nutrients discussed above.
$89.99
Frequently Asked Questions
Do glaucoma supplements cure glaucoma?
No. No supplement has been shown to cure glaucoma, reverse optic nerve damage, or restore lost vision. Lowering eye pressure is the only proven way to slow the disease.
Can supplements replace eye drops?
No. Stopping pressure treatment can cause irreversible vision loss. Talk to your ophthalmologist before changing anything.
Which supplement has the most human evidence?
Nicotinamide has the most recent trial activity, with short-term retinal signals in three small trials. A 2026 review still found the evidence insufficient for routine high-dose use [4]. No supplement has long-term proof.
Is ginkgo safe with blood thinners?
It can increase bleeding risk and interacts with warfarin, aspirin, clopidogrel, and other anticoagulants or antiplatelets. It should be stopped before surgery. Ask your doctor first.
How long before I know whether a supplement works?
Trials ran from four weeks to 18 months, and most measured tests rather than symptoms. Agree on an 8-12 week review with your eye doctor and keep a log.
Is bilberry the same as blueberry?
No. They are different fruits, and bilberry extracts are standardized differently from whole fruit, so its dose is not comparable to eating blueberries.
Does caffeine make glaucoma worse?
Mixed. In an observational analysis of 121,374 UK Biobank participants, the overall glaucoma association was null, and Mendelian randomization did not support a causal IOP effect. Compared with the lowest genetic-risk quartile consuming no caffeine, the highest genetic-risk quartile consuming at least 321 mg/day had 3.90-fold higher glaucoma prevalence [23].
What about cannabis?
It lowers IOP briefly, about 3-4 hours, but is not recommended because of side effects, impairment, and impractical dosing.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
